Faeth Therapeutics (FTH) Total Current Liabilities (2020 - 2026)

Faeth Therapeutics (FTH) has reported Total Current Liabilities for 7 consecutive years, with $9.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 147.35% year-over-year to $9.6 million; the trailing twelve-month figure through Jun 2026 stood at $9.6 million (up 147.35% YoY), and the FY2025 full-year result was $4.3 million, down 21.97% from the prior year.
• Total Current Liabilities retreated to $9.6 million in Q2 2026 per FTH's latest filing, from $14.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $14.2 million in Q1 2026 and bottomed at $3.9 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $6.5 million across 5 years, with a median of $5.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 207.31% in 2022, then slumped 37.76% in 2023.
• Over 5 years, Total Current Liabilities stood at $9.1 million in 2022, then plunged by 37.76% to $5.6 million in 2023, then retreated by 3.46% to $5.4 million in 2024, then slipped by 21.97% to $4.3 million in 2025, then surged by 125.36% to $9.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $9.6 million, $14.2 million, and $4.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.